Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.
The authors assessed CSF and plasma HIV-1 RNA and neuropsychological test performance (composite neuropsychological test Z score [NPZ-4]) in 25 HIV-1-infected subjects 4 and 8 weeks after beginning potent antiretroviral therapy that included a protease inhibitor. In the 14 subjects who entered the study on no antiretroviral treatment, NPZ-4 improvement was associated with decline in CSF HIV-1 RNA at both visits (p = 0.001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01).
Marra
C M
CM
Department of Neurology, School of Medicine, University of Washington, Seattle, USA. cmarra@u.washington.edu
Lockhart
D
D
Zunt
J R
JR
Perrin
M
M
Coombs
R W
RW
Collier
A C
AC
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D003072:Cognition Disorders / Q000097:blood / Q000134:cerebrospinal fluid / Q000209:etiology / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D012367:RNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid*; D013997:Time Factors; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy* / Q000523:psychology; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D015215:Zidovudine; D019469:Indinavir